arrow
S

Stefania Zamboni

hospital spedali civili brescia
H指数:19
被引数:1,477

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

PREDICTING CANCER-SPECIFIC MORTALITY IN NON-MUSCLE-INVASIVE BLADDER CANCER: COMPARATIVE PERFORMANCE OF AUA VS EAU RISK CLASSIFICATIONS

预测非肌层浸润性膀胱癌的癌症特异性死亡率:AUA与EAU风险分级的比较性能

2026-05-010
PRE
REAL-WORLD ADHERENCE TO EAU-RECOMMENDED NON-MUSCLE-INVASIVE BLADDER CANCER MANAGEMENT: FROM EVIDENCE-BASED PRACTICE TO ONCOLOGICAL OUTCOMES

真实世界中欧洲泌尿外科学会推荐的浅表性膀胱癌管理方案的依从性:从循证实践到肿瘤学结局

2026-05-010
PRE
CANCER-SPECIFIC SURVIVAL AFTER LOCAL RECURRENCE OR DISTANT METASTASIS FOLLOWING SURGERY FOR RENAL TUMORS: A 10-YEAR COMPARATIVE ANALYSIS

肾肿瘤术后局部复发或远处转移后的癌症特异性生存:一项10年比较分析

2026-05-010
PRE
SURVIVAL AFTER RADICAL CYSTECTOMY WITH URETEROCUTANEOSTOMY EXCEEDS CHARLSON COMORBIDITY INDEX PREDICTIONS: IMPLICATIONS FOR URINARY DIVERSION SELECTION

根治性膀胱切除伴输尿管皮肤造口术后生存率超过Charlson合并症指数预测:对尿流改道选择的启示

2026-05-010
PRE
EVALUATING THE SURROGACY OF INTERMEDIATE CLINICAL ENDPOINTS FOR OVERALL SURVIVAL IN PATIENTS WHO RECEIVED RADICAL CYSTECTOMY WITH OR WITHOUT NEOADJUVANT CHEMOTHERAPY FOR LOCALIZED MUSCLE INVASIVE BLADDER CANCER: A REAL-WORLD COHORT STUDY

评估局部肌肉浸润性膀胱癌患者接受根治性膀胱切除术(有无新辅助化疗)中,中间临床终点对总生存期的替代性:一项真实世界队列研究

2026-05-010
PRE
CANCER-SPECIFIC SURVIVAL AFTER SYNCHRONOUS OR METACHRONOUS METASTASIS FOLLOWING SURGERY FOR RENAL TUMORS: A 10-YEAR COMPARATIVE ANALYSIS

肾肿瘤术后同步或异时性转移后的癌症特异性生存率:一项10年比较分析

2026-05-010
PRE
COMPARISON OF POSTOPERATIVE COMPLICATIONS BETWEEN OPEN AND ROBOTIC PARTIAL NEPHRECTOMY: A HIGH-VOLUME SINGLE-CENTER PROPENSITY-MATCHED ANALYSIS

开放与机器人辅助部分肾切除术术后并发症的比较:一项高容量单中心倾向性匹配分析

2026-05-010
PRE
THREE-DECADE ANALYSIS OF CANCER-SPECIFIC AND OTHER-CAUSE MORTALITY AFTER SURGICAL TREATMENT FOR RENAL CELL CARCINOMA

肾细胞癌手术治疗后癌症特异性死亡率和其他原因死亡率的三十载分析

2026-05-010
PRE
SPECIFIC COMPLICATION PROFILES AFTER OPEN VS ROBOTIC PARTIAL NEPHRECTOMY: A HIGH-VOLUME SINGLE-CENTER EXPERIENCE

开放与机器人辅助部分肾切除术后的特定并发症谱:一项高容量单中心经验

2026-05-010
PRE
Real-world impact of cisplatin-based neoadjuvant chemotherapy on bladder cancer survival: a 20-year study

顺铂为基础的新辅助化疗对膀胱癌生存率的实际影响:一项20年研究

2025-10-280
PRE
Temporal trends and clinical determinants of urinary diversion after radical cystectomy

根治性膀胱切除术后尿流改道的时间趋势和临床决定因素

2025-10-010
PRE
Total and Regional Changes in Body Composition in Metastatic Hormone-sensitive Prostate Cancer Patients Randomized to Receive Androgen Deprivation + Enzalutamide ± Zoledronic Acid. The BONENZA Study

转移性激素敏感性前列腺癌患者接受雄激素剥夺+恩扎卢amide±唑来膦酸治疗后的全身及区域性体成分变化。BONENZA研究

2025-06-010
OAAI
Impact on oncological outcomes of detrusor muscle absence in pTaHG urothelial carcinoma of the bladder? The end of the jump of the lamina propria layer myth

在pTaHG膀胱尿路上皮癌中逼尿肌肌肉缺失对肿瘤学结局的影响?固有层跳跃性生长层假说的终结

2025-05-260
PRE
Contemporary outcomes in non-muscle-invasive bladder cancer: a large European multicentre study

非肌肉浸润性膀胱癌的当代结果:一项大型欧洲多中心研究

2025-05-210
OAAI
Addition of zoledronic acid to enzalutamide and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer: the randomized phase II BONENZA trial

唑来膦酸联合恩扎鲁他胺和雄激素剥夺治疗转移性激素敏感性前列腺癌: 随机II期BONENZA试验

2025-05-030
PRE
The impact of histopathological evaluation at transurethral resection of bladder tumour on survival in radical cystectomy candidates
2025-03-010
PRE
Total and regional changes in body composition in metastatic hormone-sensitive prostate cancer (mHSPC) patients randomized to receive androgen deprivation plus enzalutamide plus /- zoledronic acid: The BonEnza study

转移性激素敏感性前列腺癌(mHSPC)患者接受雄激素剥夺联合恩扎卢胺联合/不联合唑来膦酸治疗后的全身及区域身体成分变化:BonEnza研究

2024-09-010
PRE
Whole-body Diffusion-weighted Magnetic Resonance Imaging for Assessment of the Bone Response Rate in Patients with Metastatic Hormone-sensitive Prostate Cancer Receiving Enzalutamide
2024-09-012
OA
Thromboprophylaxis during neoadjuvant chemotherapy for bladder cancer reduces thromboembolism and bleeding
2024-07-030
OAAI
Relationship between circulating FSH levels and body composition and bone health in patients with prostate cancer who undergo androgen deprivation therapy: The BLADE study
2024-04-242
OA